Physician profile
Sherry Ly
NPI 1992131015
$1,205.36
in general payments reported to CMS, 2019-2025
15 companies · $253 in 2025
The $253 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $142 · 2023: $423 · 2024: $278 · 2025: $253.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heartflow, INC. | $576.92 | 2022-2025 | Ffrct |
| Actelion Pharmaceuticals US, INC. | $108.95 | 2024 | Opsumit, Uptravi |
| Amgen INC. | $96.30 | 2021-2024 | Repatha |
| Scpharmaceuticals INC. | $76.04 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $68.39 | 2024-2025 | Farxiga |
| Abbott Laboratories | $68.14 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $39.91 | 2025 | Accolade Sr |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $39.61 | 2021-2025 | Lifevest |
| Amarin Pharma, INC. | $28.71 | 2021 | |
| Novo Nordisk INC | $24.39 | 2024 | Wegovy |
| Novartis Pharmaceuticals Corporation | $20.00 | 2024 | |
| Bracco Diagnostics INC. | $19.92 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.70 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.18 | 2021 | |
| Pfizer INC. | $11.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherry Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.